{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:33:59Z","timestamp":1793392439663,"version":"4.5.0"},"reference-count":34,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"30","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["J Clin Oncol"],"published-print":{"date-parts":[[2026,10,20]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>\n                      EA1181 (ClinicalTrials.gov identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04266249\">NCT04266249<\/jats:ext-link>\n                      ) is a single-arm trial evaluating neoadjuvant taxane, trastuzumab, and pertuzumab (THP) in patients with clinical stage II\/IIIa human epidermal growth factor receptor 2 (HER2)\u2013positive breast cancer. This report focuses on the secondary end points of pathologic complete response (pCR) rates and associated factors. The primary end point\u20143-year recurrence-free survival among patients achieving a pCR (ypT0\/Tis, ypN0)\u2014will be reported when data mature.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients received four cycles of trastuzumab and pertuzumab (HP) with either once per week paclitaxel (12 weeks) or docetaxel (every 3 weeks for four cycles), followed by surgery. Clinicopathologic characteristics were assessed in all patients. The HER2DX pCR score was determined using diagnostic biopsy samples in a representative subset. Logistic regression models identified factors associated with pCR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>A total of 2,175 patients were enrolled (781 HER2+\/estrogen receptor\u2011negative [ER\u2013]; 1,394 HER2+\/ER+). Of 2,141 patients who initiated THP, the overall pCR rate was 43.8%: 63.7% in HER2+\/ER\u2013 and 32.4% in HER2+\/ER+ tumors. Higher pCR rates were observed in tumors that were ER-negative or low ER expressing, progesterone receptor-negative or low expressing, HER2 immunohistochemistry (IHC) 3+, and in patients treated with once per week paclitaxel. T3 disease was associated with a lower pCR rate in HER2+\/ER\u2013 tumors; otherwise, tumor (T) and nodal (N) stage did not significantly affect pCR. Among 569 patients assessed for HER2DX pCR scores, a high score was independently associated with higher pCR rates, after adjustment for clinicopathologic variables.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Neoadjuvant THP achieved pCR in nearly two-thirds of patients with HER2+\/ER\u2013 and one third with HER2+\/ER+ breast cancer. Low hormone receptor expression, HER2 IHC 3+ status, once per week paclitaxel use, and a high HER2DX pCR score were independent predictors of pCR. These findings should help optimize risk stratification and treatment personalization for patients with HER2-positive breast cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco-25-02255","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T20:00:09Z","timestamp":1787256009000},"page":"2919-2928","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":2,"title":["Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2\u2011Positive Breast Cancer: Secondary Analyses of EA1181\/CompassHER2 pCR"],"prefix":"10.1200","volume":"44","clinical-trial-number":[{"clinical-trial-number":"nct04266249","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1422-3734","authenticated-orcid":true,"given":"Nadine","family":"Tung","sequence":"first","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Boston, MA"},{"name":"Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengmin","family":"Zhao","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1297-4251","authenticated-orcid":true,"given":"Angela","family":"DeMichele","sequence":"additional","affiliation":[{"name":"University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8686-0236","authenticated-orcid":true,"given":"Aleix","family":"Prat","sequence":"additional","affiliation":[{"name":"Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8819-1723","authenticated-orcid":true,"given":"Eric P.","family":"Winer","sequence":"additional","affiliation":[{"name":"Yale Cancer Center, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5775-6544","authenticated-orcid":true,"given":"Jean L.","family":"Wright","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4947-6117","authenticated-orcid":true,"given":"Abram","family":"Recht","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Boston, MA"},{"name":"Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna C.","family":"Weiss","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Rochester, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy A.","family":"Tjoe","sequence":"additional","affiliation":[{"name":"Green Bay Oncology, Appleton, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheldon M.","family":"Feldman","sequence":"additional","affiliation":[{"name":"Montefiore Einstein Center for Cancer Care, Bronx, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4188-9785","authenticated-orcid":true,"given":"Gabrielle B.","family":"Rocque","sequence":"additional","affiliation":[{"name":"O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Lou","family":"Smith","sequence":"additional","affiliation":[{"name":"Research Advocacy Network, Naperville, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6069-9800","authenticated-orcid":true,"given":"Ciara C.","family":"O'Sullivan","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar D.","family":"Sardesai","sequence":"additional","affiliation":[{"name":"The Ohio State University\u2014James Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5535-4453","authenticated-orcid":true,"given":"Shou-Ching","family":"Tang","sequence":"additional","affiliation":[{"name":"LSU-LCMC Cancer Center, New Orleans, LA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6427-7373","authenticated-orcid":true,"given":"Shanu","family":"Modi","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Irvin","sequence":"additional","affiliation":[{"name":"Bon Secours Cancer Institute, Midlothian, VA"},{"name":"SCOR NCORP, Winston-Salem, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha","family":"Unni","sequence":"additional","affiliation":[{"name":"Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Battelli","sequence":"additional","affiliation":[{"name":"New England Cancer Specialists, Scarborough, ME"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9322-2451","authenticated-orcid":true,"given":"Nusayba","family":"Bagegni","sequence":"additional","affiliation":[{"name":"Washington University, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5353-0084","authenticated-orcid":true,"given":"Amy K.","family":"Krie","sequence":"additional","affiliation":[{"name":"Allima Health Cancer Institute, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mridula A.","family":"George","sequence":"additional","affiliation":[{"name":"Rutgers Cancer Institute of New Jersey, New Brunswick, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7993-1235","authenticated-orcid":true,"given":"Melinda L.","family":"Telli","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine, Stanford, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1158-7524","authenticated-orcid":true,"given":"Virginia F.","family":"Borges","sequence":"additional","affiliation":[{"name":"University of Colorado Anschutz Medical Center, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2401-9254","authenticated-orcid":true,"given":"Nina","family":"D'Abreo","sequence":"additional","affiliation":[{"name":"NYU Langone Cancer Center, NY, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5874-3390","authenticated-orcid":true,"given":"Payal","family":"Shah","sequence":"additional","affiliation":[{"name":"University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8662-3641","authenticated-orcid":true,"given":"Patricia","family":"Villagrasa","sequence":"additional","affiliation":[{"name":"Reveal Genomics SL, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8861-9980","authenticated-orcid":true,"given":"Sunil","family":"Badve","sequence":"additional","affiliation":[{"name":"Pathology, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4722-4824","authenticated-orcid":true,"given":"Ann H.","family":"Partridge","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7125-883X","authenticated-orcid":true,"given":"Kathy D.","family":"Miller","sequence":"additional","affiliation":[{"name":"Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2388-4649","authenticated-orcid":true,"given":"Lisa A.","family":"Carey","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3734-1063","authenticated-orcid":true,"given":"Antonio C.","family":"Wolff","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_14_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30716-7"},{"key":"e_1_3_14_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt182"},{"key":"e_1_3_14_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00122-4"},{"key":"e_1_3_14_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703643"},{"key":"e_1_3_14_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01159"},{"key":"e_1_3_14_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103801"},{"key":"e_1_3_14_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.05.012"},{"key":"e_1_3_14_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.0181"},{"key":"e_1_3_14_10_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-0464"},{"key":"e_1_3_14_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.8738"},{"key":"e_1_3_14_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102903"},{"key":"e_1_3_14_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02309"},{"key":"e_1_3_14_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70336-9"},{"key":"e_1_3_14_15_2","doi-asserted-by":"publisher","DOI":"10.1309\/HCF035N9WK40ETJ0"},{"key":"e_1_3_14_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djz206"},{"key":"e_1_3_14_17_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0372"},{"key":"e_1_3_14_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.0187"},{"key":"e_1_3_14_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0707056"},{"key":"e_1_3_14_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.232"},{"key":"e_1_3_14_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.3692"},{"key":"e_1_3_14_22_2","unstructured":"Grimalt: HER2DX genomic test in HER2-positive breast cancer treated with 15 weeks of neoadjuvant paclitaxel trastuzumab and pertuzumab (THP): Final analysis from the BiOnHER clinical trial. 2025"},{"key":"e_1_3_14_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00429-7"},{"key":"e_1_3_14_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70080-4"},{"key":"e_1_3_14_25_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-022-01587-z"},{"key":"e_1_3_14_26_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0239"},{"key":"e_1_3_14_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.1268"},{"key":"e_1_3_14_28_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.3824"},{"key":"e_1_3_14_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw262"},{"key":"e_1_3_14_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.6288"},{"key":"e_1_3_14_31_2","doi-asserted-by":"crossref","unstructured":"Gao H-F: De-escalated neoadjuvant taxane plus trastuzumab and pertuzumab with or without carboplatin in HER2-positive early breast cancer (neoCARHP): A multicentre open-label randomised phase 3 trial. 2025","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA500"},{"key":"e_1_3_14_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00581-3"},{"key":"e_1_3_14_33_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00280"},{"key":"e_1_3_14_34_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266384"},{"key":"e_1_3_14_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00104-9"}],"updated-by":[{"DOI":"10.1200\/jco-26-02664","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:00:00Z","timestamp":1793318400000}}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO-25-02255","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:59:10Z","timestamp":1793390350000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-25-02255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":34,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2026,10,20]]}},"alternative-id":["10.1200\/JCO-25-02255"],"URL":"https:\/\/doi.org\/10.1200\/jco-25-02255","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1200\/JCO.26.1008","asserted-by":"subject"}]},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]},"assertion":[{"value":"2025-09-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}